Omeros Corporation OMER Fundamentals and Key Ratios

Home
Investing
Stocks
USA
NASDAQ
Omeros Corporation (OMER)
Omeros Corporation (OMER) Financials

Omeros Corporation (OMER) Fundamentals


Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.

SHARE INFORMATION
Market Cap	$ 457,393,409
Shares Outstanding	62,828,765
Float	62,798,765
Percent Float	99.95%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 375,000
Latest Fiscal EPS	$ 0.00
Latest Fiscal Date	2023-03-31

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	256
Institutional Holdings Date	2023-03-31
Institutional Bought Previous 3 Months	1,238,675
Institutional Holdings Percent	48.6%
Institutional Sold Previous 3 Months	4,998,573
Insider Holdings Date	2023-03-31
Insider Bought Previous 3 Months	-
Insider Holdings Percent	4.1
Insider Sold Previous 3 Months	-
Insider Shares Owned	2,603,510

TRADING INFO
52 Week High	$ 7.75
52 Week Low	$ 1.74
52 Week High Change	$ 200.83
21 Day Moving Average	$ 5.7379
21 Day Extended Moving Average	$ 5.9041
50 Day Moving Average	$ 5.393
50 Day Extended Moving Average	$ 5.3871
200 Day Moving Average	$ 3.9068
200 Day Extended Moving Average	$ 4.5495
10 Day Average Volume	667,418
20 Day Average Volume	567,305
30 Day Average Volume	591,610
50 Day Average Volume	522,844
Alpha	-0.005927
Beta	1.0671
Standard Deviation	0.214636
R2	0.071403
7 Day Price Change	$ 1.56
7 Day Percent Change	27.27%
21 Day Price Change	$ 1.82
21 Day Percent Change	33.21%
30 Day Price Change	$ 1.62
30 Day Percent Change	28.62%
Month to Date Price Change	$ 1.08
Month to Date Percent Change	17.42%
Quarter to Date Price Change	$ 2.63
Quarter to Date Percent Change	56.56%
180 Day Price Change	$ 5.18
180 Day Percent Change	246.67%
200 Day Price Change	$ 4.54
200 Day Percent Change	165.69%
Year to Date Price Change	$ 5.02
Year to Date Percent Change	222.12%

Omeros Corporation (OMER) Key Ratios

PROFITABILITY
EBIT Margin	-13,797.9%
EBITDA Margin	-13,810.5%
Pre-Tax Profit Margin	-569.0%
Profit Margin Count	-89.87%
Gross Margin	100.0%
Profit Margin TOT	-89.87%

INCOME STATEMENTS
Revenue	$ 375,000
Revenue Per Share	$ 0.006
Revenue (3 Years)	$ 0.00
Revenue (5 Years)	$ 0.00

FINANCIAL STRENGTH
Price to Tangible Book	10.50
Total Debt To Equity	9.00
Int Coverage	0.00
Current Ratio	2.50
Leverage Ratio	16.00
Quick Ratio	2.40
Long Term Debt To Capital	0.80

VALUATION MEASURES
PE Ratio	0.00
Enterprise Value	$ 353,974,343
Price to Sales	307.26
Price to Free Cash	0.50
PE High Last 5 Years	0.00
Price To Book	10.50
Price To Cash Flow	0.50
PE Low Last 5 Years	0.00
Price to Tangible Book	10.50

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0.20
Invoice Turnover	0.00
Assets Turnover	0.00
Return Assets	-27.56
Return on Equity	-893.25
Return on Capital	-32.41

Omeros Corporation (OMER) Profile

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	-
CEO	Gregory A. Demopulos
Employees	213
Last Audit	-
CIK	0001285819
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)

CONTACT INFO
Address	201 Elliott Avenue West Seattle, WA 98119
Website	https://www.omeros.com
Facsimile	+1 206 676-5005
Telephone	+1 206 676-5000
Email	-

Boards:

Quotes:

OMER